Floatz logo

LYSINE

GIST

ITM Solucin GmbHSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the GIST cohort.

Asset / SponsorPhaseRating
Regorafenib
Institut Bergonié
Phase 4BBB
Avapritinib
Blueprint Medicines Corporation
Phase 3BB
Her-2 Vaccine
Robert Wesolowski
Phase 1CC
Tas-102
AEterna Zentaris
Phase 1CC
Perifosine
AEterna Zentaris
Phase 1CC

View all 9 →

Same molecule, other indications

LYSINE is also rated in:

Neuroendocrine TumorsDormant
B
Indicative ·
59 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
NETsDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →